Margaret von Mehren, MD
Ripretinib (DCC-2618) improved progression-free survival (PFS) compared with placebo in patients with fourth-line and fourth-line plus advanced gastrointestinal stromal tumors (GIST), according to topline findings of the phase III INVICTUS study (NCT03353753).
“Today’s announcement represents a significant milestone in our mission to deliver important new medicines for the treatment of cancer,” Steve Hoerter, president and chief executive officer of Deciphera, stated in the press release. “The data from INVICTUS reinforce our belief that ripretinib has the potential to transform the treatment of GIST, and our focus now turns to working closely with the FDA as they evaluate ripretinib for those patients with GIST who, having failed all currently approved therapies, are in desperate need of a treatment option.”
Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors. Deciphera. Published August 13, 2019. https://bit.ly/2OTQIsg. Accessed August 13, 2019.
... to read the full story